Andrea Anderson covers genomics research studies and translational research for GenomeWeb. Find her on Twitter at @andyandy_tk.
A Phase II trial is pursuing molecularly targeted treatments for CUP as a different Phase III trial failed to find benefit for expression-based primary site therapies.
The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.
Investigators plan to profile clonal hematopoiesis in a broad range of patients to get a clearer look at its interactions with aging and disease.
Since 2016, the VHA has routinely profiled molecular features in advanced cancers from vets in its care, even in rural locales, though challenges remain.
A New York Genome Consortium-led team plans retrospective and prospective analyses on very rare cancers in the hopes of improving treatment options available for patients.
The mCODE team recently released standards for inputting genomic and other data into patient records to boost patient record transferability and trial participation.
By profiling hereditary risk variants in women with breast cancer, researchers hope to lay the foundation for future genetic testing programs in the Caribbean country.
Olaparib maintenance therapy stretched out progression-free survival, suggesting a need for germline BRCA1/2 mutation testing in pancreatic cancer patients.
Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.
To understand the evolution of brain conditions and other traits, investigators plan to sequence human and pathogen DNA in thousands of samples from Europe.
University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.
In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.